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Searching for autoimmunity in AD
Atopic dermatitis (AD) is increasing worldwide, and environ-
mental factors and allergens have been suggested to play a role 
in determining disease expression. Although the involvement 
of immune mechanisms against self-components has been 
proposed, the role of autoimmunity in AD is unclear. Tang and 
colleagues recently performed a systematic literature review 
to evaluate the prevalence and specificity of autoreactivity in 
AD patients as well as to determine whether clinical disease 
severity was correlated with autoreactivity. Of the 1,408 studies 
describing autoimmunity and AD or eczema, 31 were deemed 
suitable for inclusion in this meta-analysis. In 14 of these stud-
ies, autoreactivity was reported in 18–91.4% of 1,253 AD 
patients and in only 0–11.7% of controls. In AD patients, IgE 
autoreactivity is a specific phenomenon because no such asso-
ciation was detected in healthy patients or in those with other 
atopic or inflammatory conditions. Unequivocal determination 
of the role of autoimmunity in AD is important because such 
information may lead to new therapies to inhibit the develop-
ment and progression of autoimmunity; thus, longitudinal 
studies of this concept are necessary. (J Allergy Clin Immunol 
129:1209–15, 2012) Selected by B. Gilchrest
Commensal calibration
Previous studies indicated that commensal bacterial commu-
nities, which colonize the skin and vaginal, upper respiratory, 
and gastrointestinal tracts, alter a patient’s susceptibility to dia-
betes, cancer, allergy, and infection, although the mechanisms 
that underlie this influence remain unknown. Abt and col-
leagues found that the manipulation of commensal bacteria 
in antibiotic-treated (ABX) mice resulted in impaired protec-
tive immunity in the face of infection with either lymphocyte 
choriomeningitis virus or influenza virus. Both adaptive and 
innate antiviral immune responses were affected in these mice. 
Interestingly, genome-wide transcriptional profiling in combi-
nation with functional studies revealed defective expression 
of antiviral defense genes in macrophages from the ABX mice. 
Together, these data suggest that signals from commensal bac-
teria calibrate the activation threshold of the innate antiviral 
immune response. The findings offer hope that manipulation 
of bacteria via probiotic treatment or bacteriotherapy will be 
useful for improving antiviral responses in humans. (Immunity 
37:158–70, 2012) Selected by M. Amagai
Implicate the innate
Psoriasis relapses have been inadvertently induced in patients 
and mice by treatment with Aldara, a cream that contains 
imiquimod. This observation implicates T helper type 17 
effector cells in psoriasis. Pantelyushin and colleagues utilized 
a mouse model to demonstrate that initiation of plaque for-
mation following Aldara treatment is dependent on skin-infil-
trating γδ T cells that express the RAR-related orphan receptor 
gamma (RORγt) transcription factor and on innate lymphoid 
cells (ILCs). IL-17A, IL-17F, and IL-22 were found to be criti-
cal for psoriatic plaque formation, and RORγt+ γδ T cells and 
ILCs were the predominant producers of these cytokines in this 
model. The study establishes the sufficiency of a dysregulated 
innate immune compartment for psoriatic plaque formation. (J 
Clin Invest 122:2252–6, 2012) Selected by S. Hwang
Next phase for BCC treatment
Basal cell carcinoma (BCC), the most common cancer, is 
typically treated surgically; however, no effective treatment 
is available for advanced or metastatic disease. Dysregulated 
hedgehog signaling has been implicated in the pathogenesis of 
BCC, and vismodegib (GDC-0449, Genentech), a small-mol-
ecule inhibitor of this signaling pathway, has shown promise 
for treatment of advanced BCC in a phase I trial. Sekulic and 
colleagues recently performed a multicenter, international, 
nonrandomized study of vismodegib in 96 patients with locally 
advanced or metastatic BCC. The response rate was 30% in 
33 metastatic BCC patients and 43% in 63 locally advanced 
BCC patients. Unfortunately, 25% of patients reported serious 
adverse effects, and fatal events were noted in seven cases. 
Despite these side effects, this phase II trial demonstrated 
that vismodegib treatment is an effective new treatment for 
advanced BCC, and it led to the approval of the drug by the 
US Food and Drug Administration. (N Engl J Med 366:2171–9, 
2012) Selected by E. Lerner
Signal for solar injury
Exposure to UVB solar radiation evokes an inflammatory reac-
tion of the skin, and this reaction has been characterized by 
activation of NF-κB and induction of cytokines, including IL-6 
and tumor necrosis factor-a (TNF-a), which exerts pleiotropic 
downstream effects after solar injury. Bernard and colleagues 
recently found that RNA that is released from keratinocytes 
upon exposure to UVB radiation stimulates production of 
TNF-a and IL-6. Using whole-transcriptome shotgun sequenc-
ing, these investigators demonstrated that these small nuclear 
RNAs formed double-stranded RNAs to activate Toll-like recep-
tor 3 (TLR3), which is required for this inflammatory response 
to UVB. In vivo, UVB-irradiated U1 RNA induced redness 
and increased ear thickness in mouse ears and increased 
the expression of TNF-a and IL-6 in wild-type but not TLR3-
deficient mice, confirming the role of these RNA molecules in 
induction of the inflammatory response. Thus, self-RNAs sig-
nal UVB solar damage via TLR3, and these results suggest that 
these molecules may be useful biomarkers or therapy targets 
for photodamage disorders. (Nat Med, published online 8 July 
2012; doi:10.1038/nm.2861) Selected by B. Gilchrest
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